INM InMed Pharmaceuticals Inc

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 18, 2024

 

InMed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

Suite 1445 - 885 West Georgia Street Vancouver, B.C. Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

 

(Registrant’s Telephone Number, Including Area Code): (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07: Submission of Matters to a Vote of Security Holders.

 

On December 18, 2024, InMed Pharmaceuticals Inc. (the “Corporation”) held its 2024 Annual General Meeting of Shareholders (the “Meeting”).  At the Meeting, all items of business were voted upon by the shareholders, as indicated below:

 

Proposal No. 1—Election of Directors

 

The Corporation’s shareholders approved the election of four director nominees to hold office until the 2025 Annual General Meeting of Shareholders or until their successors are elected or appointed. The election of Ms. Janet Grove was withheld and as such, in accordance with the Corporation’s Majority Voting Policy (the “Majority Voting Policy”), Ms. Grove has tendered her resignation to the chair of the Corporation’s Board of Directors (the “Board”). The Board’s Nominating & Governance Committee will, in accordance with the terms of the Majority Voting Policy, make a determination in due course on whether it will ultimately recommend to the Board to accept Ms. Grove’s resignation. A further update will be provided following the completion of the Nominating & Governance Committee’s assessment and upon the Board’s determination.

 

Results of the vote for the election of the Board at the Meeting are set out as follows:

 

Nominee		Votes For*				% Votes For				Votes Withheld*				%Votes Withheld				Broker Non-Votes*
Eric A. Adams			1,358,271				96.67	%			46,802				3.33	%			3,913,604
Andrew Hull			1,358,517				96.69	%			46,556				3.31	%			3,913,604
Janet Grove			621,901				44.26	%			783,172				55.74	%			3,913,604
Bryan Baldasare			1,358,152				96.66	%			46,921				3.34	%			3,913,604
Nicole Lemerond			1,358,261				96.67	%			46,812				3.33	%			3,913,604

 

*	Share amounts do not reflect the Corporation’s previously disclosed 1-for-20 reverse stock split, which was completed in November 2024 (the “November Reverse Stock Split”).

 

Proposal No. 2—Appointment of Independent Registered Public Accounting Firm

 

The Corporation’s shareholders voted at the Meeting to approve the appointment of Marcum LLP (now operating as CBIZ LLP following a recent merger) as the independent registered public accounting firm of the Corporation until the 2025 Annual General Meeting of Shareholders or until a successor is named.

 

Votes For*		% Votes For		Vote Against		% Votes Against		Abstain*		Broker Non-Votes
4,983,918		93.706%		0		0%		334,759		0

 

*	Share amounts do not reflect the Corporation’s previously disclosed November Reverse Stock Split.

 

Item 7.01 Regulation FD Disclosure.

 

On December 18, 2024, the Corporation issued a press release announcing the voting results of the Meeting and other related matters. A copy of the press release is furnished hereto as Exhibit 99.1.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit 99.1.		Press release, dated December 18, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  December 19, 2024

 

	INMED PHARMACEUTICALS INC.
	By:	/s/ Eric A. Adams
	Name:	Eric A. Adams
	Title:	Chief Executive Officer

 

 

2

Exhibit 99.1

 

NASDAQ: INM   1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com

 

InMed Announces Results of 2024 Annual General Meeting

 

Vancouver, British Columbia – December 18, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholders held on December 18, 2024 (the “Meeting”), the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 28, 2024, were voted upon by the shareholders. A total of 5,318,677 common shares of the Company, representing approximately 39.83% of the Company’s 13,353,431 issued and outstanding common shares, were represented in person or by proxy at the Meeting.

 

Shareholders approved the election of four director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. The election of Ms. Janet Grove was withheld and as such, in accordance with the Company’s Majority Voting Policy (the “Majority Voting Policy”), Ms. Grove has offered her resignation to the chair of the Board. The Nominating & Governance Committee will, in accordance with the Majority Voting Policy, consider her resignation and make a determination in due course on whether or not it will recommend to the Board to accept Ms. Grove’s resignation. A further update will be provided promptly following the Board’s determination.

 

Results of the vote for the election of the board of directors (the “Board”) at the Meeting are set out as follows:

 

		Votes For								Withheld Votes
Director		Number				Percentage				Number				Percentage
Eric A. Adams			1,358,271				96.67	%			46,802				3.33	%
Janet Grove			621,901				44.26	%			783,172				55.74	%
Andrew Hull			1,358,517				96.69	%			46,556				3.31	%
Nicole Lemerond			1,358,261				96.67	%			46,812				3.33	%
Bryan Baldasare			1,358,152				96.66	%			46,921				3.34	%

 

Shareholders also voted to approve Marcum LLP (now doing business as CBIZ LLP) as the Company’s auditors for the following year. No other matters were brought before the meeting.

 

InMed filed a report of voting results on SEDAR at www.sedarplus.ca on December 18, 2024.

 

About InMed:

 

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

 

 

Investor Contact:

 

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1 604 416 0999

E: ir@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs.

 

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

 

 

v3.24.4

Cover	Dec. 18, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 18, 2024
Entity File Number	001-39685
Entity Registrant Name	InMed Pharmaceuticals Inc.
Entity Central Index Key	0001728328
Entity Tax Identification Number	98-1428279
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	Suite 1445 - 885 West Georgia Street
Entity Address, City or Town	Vancouver
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6C 3E8
City Area Code	604
Local Phone Number	669-7207
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	INM
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

---